The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
J Parkinsons Dis
; 10(s1): S65-S73, 2020.
Article
en En
| MEDLINE
| ID: mdl-32651333
ABSTRACT
When oral dopaminergic medication falls short in the treatment of Parkinson's disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Apomorfina
/
Carbidopa
/
Levodopa
/
Estimulación Encefálica Profunda
/
Antiparkinsonianos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
J Parkinsons Dis
Año:
2020
Tipo del documento:
Article
País de afiliación:
Países Bajos